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system were reviewed. IORT-related effects and early 
postoperative outcome were assessed.  
Results: Seventy eight patients (median age 67 years) 
underwent lumpectomy, sentinel lymph node biopsy, and 
concurrent IORT from march 2013 to march 2014. Ninety-five 
percent of patients had invasive ductal histology with a 
median tumor size of 1.5 cm.  
Conclusions: While a variety of APBI techniques are currently 
available for clinical use, our early Latin American operative 
experience with IORT shows it is well tolerated with low 
morbidity. The addition of WBI may be necessary in situations 
for positive residual margins or microscopic nodal disease in 
patients who do not undergo additional surgery. 
Implementation of IB impacts treatment planning and 
operating room use in a multidisciplinary breast cancer 
program. The safety profile, ease of administration, and 
reduced costs of IB favor its more widespread use in selected 
patients with early-stage breast cancer. 
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Purpose/Objective: The Intrabeam system is a miniature 
accelerator emitting a 50 kV isotropic radiation. Its flat and 
surface applicators convert a spherical dose distribution into 
a flat one. This study aims at characterizing the dosimetric 
behaviour of these applicators for dermatologic applications. 
Materials and Methods: Dosimetric characterization was 
carried out in two steps. Firstly characterization was made in 
standard conditions for dermatologic applications, which is 
with the applicator directly on contact with the skin. 
Secondly, characterization was made in more clinical 
conditions, with obliquities and heterogeneities. 
Results: Behaviours of flat and surface applicators are 
different and have already been studied before. In standard 
conditions, dose rates and dose distribution results differ 
from previously published studies due to differences in the x-
ray source design. The study showed that when contact 
between the applicator and the skin of the patient is not 
perfect there is a dose distribution spread on the edge of the 
irradiation field where the contact is not made. Dose loss due 
to lack of backscatter radiations is significant. By contrast, 
influence of a denser material behind the measurement point 
has no significant influence on the dose at this point. 
Thickness of tissue treated with flat and surface applicators 
is only a few millimetres, depending on the applicator's size. 
Conclusions: The INTRABEAM® system with surface and flat 
applicators is a reliable way of treating superficial cutaneous 
malignancies as long as there is a good contact between the 
applicator and the skin.  
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Purpose/Objective: The main purpose of this study was to 
investigate the capability of EBT3 Gafchromic films to 
measure the delivered dose to the tumour bed and skin for 
intraoperative radiotherapy under clinical conditions in order 
to implement a protocol for in vivo dosimetry. 
Materials and Methods: This work has been performed using 
the 50 kV X-ray source from the Intrabeam® instrument (Carl 
Zeiss, Germany). EBT3 Gafchromic films were characterised 
within a water phantom and then used for in vivo dosimetry.  
Results: EBT3 Gafchromic films were found to be feasible for 
in vivo dosimetry. Measurements were performed in 10 
patients resulting in measured doses from 9.04 to 17.71 Gy in 
the tumour bed and from 0.87 to 3.98 Gy on the skin.  
Conclusions: EBT3 Gafchromic films offered an accurate 
method for the measurement of both the tumour bed and 
skin.  
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Purpose/Objective: Head and neck squamous cell carcinoma 
(HNSCC) is frequently characterized by overexpression of 
anti-apoptotic Bcl-2 family members. Increased levels of 
these anti-apoptotic proteins has been associated with radio- 
and chemoresistance and poor clinical outcome. Inhibition of 
anti-apoptotic Bcl-2 family members therefore represents an 
appealing strategy to overcome resistance to anticancer 
therapies. The aim of this study was to show enhanced 
radiation-induced tumor cell kill in HNSCC tumor cell lines in 
vitro, upon combined treatment with the pan-Bcl-2 inhibitor 
AT-101 and radiation. Additionally, we aimed to compare the 
effective in vitro concentrations with human serum levels of 
AT-101 obtained from a phase I/II trial, to substantiate 
therapeutic opportunities. 
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Materials and Methods: In vitro, we examined the effect of 
AT-101 (kindly provided by Ascenta Therapeutics Inc.) 
radiation and the combination on apoptosis induction and 
clonogenic survival in two HNSCC cell lines that expressed 
the target proteins: UM-SCC-11B (derived from a primary 
tumor of the larynx) and VU-SCC-OE (derived from a primary 
tumor of the oral cavity). Apoptosis was determined by bis-
benzimide staining to detect morphological nuclear changes 
and/or by propidium iodide staining and flow-cytometry 
analysis to quantify sub-diploid apoptotic nuclei. The type of 
interaction between AT-101 and radiation was evaluated by 
determining the Combination Index (CI) and isobolographic 
analysis. In addition, we assessed clonogenic survival upon 
combined treatment in the VU-SCC-OE cell line. In the 
clinical study, N07CRH, patients with locally advanced 
HNSCC, were enrolled in a two-arm trial design with standard 
radiotherapy/cisplatin treatment combined with concurrent 
dose-escalating oral AT-101 according to two different 
schedules, a 2-weeks daily schedule every 3 weeks, and a 
pulse-dose schedule on 3 consecutive days, every 3 weeks. 
Blood samples were collected and serum concentrations of 
AT-101 were determined by HPLC methods. 
Results: In vitro results showed that AT-101 (10-15 μM) 
enhances radiation(5Gy)-induced apoptosis with CI's ranging 
from 1.1 (additive) to 0.74 (synergistic). Clonogenic survival 
assays showed a radiosensitizing effect with a DEF37 of 1.3 at 
concentrations of AT-101 that were markedly lower than used 
for apoptosis studies. Patients tolerated AT-101 well up to 
doses of 20 mg. Pharmacokinetic analyses of blood samples 
taken from the patients at time intervals from 30 minutes up 
to 24 hours after oral intake showed a dose-dependent 
increase in serum concentration with peak concentrations up 
to 300 - 700 ng/ml (0.5 – 1.2 μM) between 2 and 2.5 hours 
after intake. 
Conclusions: AT-101 is a competent enhancer of radiation-
induced apoptosis in HNSCC in vitro. In addition, in vitro 
radiosensitization was observed at clinically achievable serum 
levels. These finding support further evaluation of the 
combination of AT-01 with radiation in Bcl-2-overexpressing 
tumors.  
   
PO-1061   
Radiosensitisation properties of PI3K/AKT inhibitor GDC-
0941 in prostate cancer cells 
R. Floyd1, N. McDermott1, A. Meunier1, L. Marignol1 
1Trinity Centre for Health Sciences, Radiation Therapy Dept., 
Dublin 8, Ireland Republic of  
 
Purpose/Objective: Radiation therapy is a primary treatment 
modality for prostate cancer. Over activation of the 
phosphoinositide 3-kinase (PI3K) pathway causes 
radioresistance increasing cell survival following radiation, 
resulting in treatment failure and disease recurrence. 
Downstream effects of PI3K increase HIF1-α concentrations 
resulting in high levels of hypoxia in PI3K activated prostate 
cancer cells. This study investigated the effect of PI3K 
inhibitor, GDC-0941, on the radiosensitisation of cell lines 
DU145 and 22Rv1 under hypoxic and normoxic conditions. 
Materials and Methods: GDC-0941 was combined with 
radiation treatment to assess the radiosensitisation effect in 
DU145 and 22Rv1 cell lines. GDC-0941 was also tested under 
hypoxic conditions to assess if radiosensitivity was 
maintained. Clonogenic assays were used to assess cell 
survival under the varied treatment conditions. 
Results: GDC-0941 was shown to enhance radiosensitivity in 
both 22Rv1 (2Gy: SER=1.7, p=0.038) and DU145 (2Gy: SER=2, 
p=0.0025). The radiosensitisation conferred was also 
significant under hypoxic conditions in 22Rv1 (2Gy: SER=2, 
p=0.0155) although non-significant in DU145 (2Gy: SER=1.1, 
p=0.1835). GDC-0941 showed comparable radiosensitisation 
under both normoxic and hypoxic conditions in both cell 
lines. 
Conclusions: GDC-0941 radiosensitised prostate cancer cells 
under hypoxic and normoxic conditions. 
   
PO-1062   
Radiosensitization of tumor cells by Paclitaxel relies on 
chromosome missegregation and depends on TPX2 
M. Orth1, C. Belka1, K. Lauber1 
1Klinik und Poliklinik für Strahlentherapie und 
Radioonkologie, Radiation Oncology, München, Germany  
 
Purpose/Objective: The anti-neoplastic compound Paclitaxel 
(Taxol®) is adopted for multiple strategies of cancer 
treatment encompassing classic chemotherapy on the one 
side as well as adjuvant treatment settings that combine 
chemotherapy with other treatment modalities like radiation 
therapy on the other. The molecular mechanism(s) by which 
Paclitaxel exerts radiosensitization of tumor cells is not 
understood in full detail. Moreover, the doses of Paclitaxel 
that are currently applied in the clinic often coincide with 
side effects of major severity. Finally, no stratification 
markers that allow for predicting the responsiveness of 
tumors towards treatment schedules involving Paclitaxel and 
radiotherapy are available thus far. 
Materials and Methods: Multiple concentrations of Paclitaxel 
were screened for respective effects on the viability and the 
proliferation of tumor cells. After identifying low nanomolar 
doses of Paclitaxel to impact tumor cell proliferation and – 
viability in a hitherto highly neglected manner, a cohort of 
tumor cell lines was screened for individual differences in 
susceptibility towards equivalent doses of Paclitaxel, either 
administered alone or in combination with irradiation. Based 
on this screen, a search for new stratification markers was 
performed.  
Results: We show that Paclitaxel at lower nanomolar 
concentrations effectively sensitizes tumor cells towards 
ionizing radiation by facilitating high-grade aneuploidization. 
At such concentrations, Paclitaxel renders the ordinary, 
bipartite mode of cell division into a highly non-equational, 
mainly tripartite one thereby facilitating huge levels of 
aneuploidization and this is frequently followed by a distinct 
kind of apoptotic cell death. We show that this effect can be 
correlated with Paclitaxel-dependent radiosensitization of 
tumor cells since cell lines that are resistant to it are 
sensitized to lesser extends. We also provide evidence that 
both, Paclitaxel-dependent aneuploidization and – 
radiosensitization of tumor cells correlate with the 
expression levels of AURKA and TPX2, two proteins involved 
in mitotic spindle assembly, since a knockdown of TPX2 not 
only rescues the bipartite mode of cell division in the 
presence of Paclitaxel but also diminishes the 
radiosensitization effect that is achieved by Paclitaxel.  
